Wall Street Zen Upgrades Neuphoria Therapeutics (NASDAQ:NEUP) to Hold

Neuphoria Therapeutics (NASDAQ:NEUP) was upgraded by equities research analysts at Wall Street Zen to a “hold” rating in a report issued on Saturday.

A number of other equities research analysts also recently weighed in on the company. HC Wainwright downgraded Neuphoria Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research report on Monday, June 1st. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $21.00.

Neuphoria Therapeutics Trading Down 7.1%

Shares of Neuphoria Therapeutics stock opened at $3.64 on Friday. The business has a 50-day moving average price of $4.29 and a two-hundred day moving average price of $4.39. Neuphoria Therapeutics has a 1-year low of $3.19 and a 1-year high of $21.40. The company has a market cap of $19.66 million, a P/E ratio of -0.33 and a beta of 0.74.

Neuphoria Therapeutics (NASDAQ:NEUP) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.47. Equities research analysts forecast that Neuphoria Therapeutics will post -4.07 EPS for the current fiscal year.

Institutional Trading of Neuphoria Therapeutics

Several large investors have recently made changes to their positions in NEUP. AdvisorShares Investments LLC increased its position in Neuphoria Therapeutics by 15.8% in the 1st quarter. AdvisorShares Investments LLC now owns 155,367 shares of the company’s stock valued at $632,000 after buying an additional 21,173 shares in the last quarter. XTX Topco Ltd acquired a new stake in Neuphoria Therapeutics in the fourth quarter valued at approximately $47,000. Ikarian Capital LLC acquired a new stake in Neuphoria Therapeutics in the fourth quarter valued at approximately $184,000. Boothbay Fund Management LLC bought a new stake in shares of Neuphoria Therapeutics during the fourth quarter valued at approximately $54,000. Finally, Bridgeway Capital Management LLC bought a new stake in shares of Neuphoria Therapeutics during the fourth quarter valued at approximately $57,000. 15.90% of the stock is currently owned by institutional investors and hedge funds.

Neuphoria Therapeutics Company Profile

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.